Voyager Therapeutics Inc
NASDAQ:VYGR

Watchlist Manager
Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc
NASDAQ:VYGR
Watchlist
Price: 5.75 USD Market Closed
Market Cap: 314.1m USD
Have any thoughts about
Voyager Therapeutics Inc?
Write Note

Voyager Therapeutics Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Voyager Therapeutics Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Voyager Therapeutics Inc
NASDAQ:VYGR
Retained Earnings
-$291.7m
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Retained Earnings
-$5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Retained Earnings
-$25.5B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Retained Earnings
$8.7B
CAGR 3-Years
53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Retained Earnings
$30.8B
CAGR 3-Years
22%
CAGR 5-Years
36%
CAGR 10-Years
71%
No Stocks Found

Voyager Therapeutics Inc
Glance View

Market Cap
313.6m USD
Industry
Biotechnology

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.

VYGR Intrinsic Value
5.02 USD
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Voyager Therapeutics Inc's Retained Earnings?
Retained Earnings
-291.7m USD

Based on the financial report for Sep 30, 2024, Voyager Therapeutics Inc's Retained Earnings amounts to -291.7m USD.

What is Voyager Therapeutics Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
1%

Over the last year, the Retained Earnings growth was 8%. The average annual Retained Earnings growth rates for Voyager Therapeutics Inc have been 6% over the past three years , 1% over the past five years .

Back to Top